RhumbLine Advisers’s Crescent Biopharma CBIO Stock Holding History

RhumbLine Advisers’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$459K	Buy	+25,487	New	+$498K	﹤0.01%	2831
2024 Q3	–	Sell	-10	Closed	-$294	–	4249
2024 Q2	$294	Hold	10	–	–	﹤0.01%	4309
2024 Q1	$3.13K	Hold	10	–	–	﹤0.01%	4041
2023 Q4	$2.46K	Hold	10	–	–	﹤0.01%	4077
2023 Q3	$1.57K	Hold	10	–	–	﹤0.01%	4139
2023 Q2	$1.82K	Buy	+10	New	+$1.68K	﹤0.01%	4227
2021 Q2	–	Sell	-607	Closed	-$183K	–	3039
2021 Q1	$183K	Hold	607	–	–	﹤0.01%	2852
2020 Q4	$228K	Buy	607 +79	+15%	+$27.7K	﹤0.01%	2782
2020 Q3	$162K	Sell	528 -61	-10%	-$23.3K	﹤0.01%	2748
2020 Q2	$221K	Buy	589 +147	+33%	+$41.6K	﹤0.01%	2725
2020 Q1	$101K	Hold	442	–	–	﹤0.01%	2777
2019 Q4	$234K	Buy	442 +3	+0.7%	+$1.62K	﹤0.01%	2696
2019 Q3	$189K	Sell	439 -4	-0.9%	-$2.57K	﹤0.01%	2764
2019 Q2	$528K	Buy	443 +10	+2%	+$12K	﹤0.01%	2337
2019 Q1	$540K	Sell	433 -13	-3%	-$14.9K	﹤0.01%	2301
2018 Q4	$422K	Buy	446 +144	+48%	+$173K	﹤0.01%	2377
2018 Q3	$435K	Sell	302 -18	-6%	-$27.2K	﹤0.01%	2332
2018 Q2	$516K	Buy	+320	New	+$550K	﹤0.01%	2301

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RhumbLine Advisers's CBIO Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 25,487 shares worth $459K. The stake represents ﹤0.01% of the portfolio and ranks #2831 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in CBIO as recently as Q2 2024.

RhumbLine Advisers first reported a position in CBIO in Q2 2018 and has held it in 18 quarters since. The position peaked at $540K in Q1 2019. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

RhumbLine Advisers held 25,487 shares of Crescent Biopharma worth $459K as of Q2 2026.
Crescent Biopharma was a new RhumbLine Advisers position in Q2 2026.
Crescent Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2831 holding.
RhumbLine Advisers first reported a position in Crescent Biopharma in Q2 2018 and has held it in 18 quarters since.
RhumbLine Advisers's Crescent Biopharma position peaked at $540K in Q1 2019.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.